Review Article
The role of a national cancer registry in effective implementation and monitoring of the Global Breast Cancer Initiative (GBCI) framework in Ghana: a narrative review
Translational Breast Cancer Research
2025;
6:
20
(30 April 2025)
Review Article
Non-commonly prescribed physical exercises, disciplines and sports in breast cancer survivors: a narrative review
Translational Breast Cancer Research
2025;
6:
19
(30 April 2025)
Review Article
Radiotherapy in breast cancer patients achieving nodal pathologic complete response after neoadjuvant therapy: a scoping review
Translational Breast Cancer Research
2025;
6:
18
(30 April 2025)
Review Article
Preoperative partial breast radiation for favorable early-stage breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
17
(30 April 2025)
Review Article
Breast cancer screening for transgender individuals with breast cancer susceptibility genes
Translational Breast Cancer Research
2025;
6:
16
(30 April 2025)
Review Article
Contrast-enhanced mammography in high-dense breasts: a narrative review
Translational Breast Cancer Research
2025;
6:
15
(30 April 2025)
Review Article
De-escalation of axillary interventions in the management of breast cancer patients following neoadjuvant systemic treatment
Translational Breast Cancer Research
2025;
6:
14
(30 April 2025)
Review Article
Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy—what are future possibilities?—a narrative review
Translational Breast Cancer Research
2025;
6:
13
(30 April 2025)
Original Article
Enhancing patient education in breast surgery: artificial intelligence-powered guidance for mastopexy, augmentation, reduction, and reconstruction
Translational Breast Cancer Research
2025;
6:
12
(30 April 2025)
Editorial Commentary
DESTINY-Breast06 continues to explore HR+, HER2-negative metastatic breast cancer beyond DESTINY-Breast04
Translational Breast Cancer Research
2025;
6:
11
(24 January 2025)
Editorial Commentary
Understanding the NATALEE trial—from a methodologist stand of point
Translational Breast Cancer Research
2025;
6:
10
(24 January 2025)
Review Article
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
9
(24 January 2025)
Review Article
Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
8
(24 January 2025)
Review Article
Neurological symptom management in breast cancer meningeal carcinomatosis
Translational Breast Cancer Research
2025;
6:
7
(24 January 2025)
Review Article
Modern approaches to lymphatic surgery: a narrative review
Translational Breast Cancer Research
2025;
6:
6
(24 January 2025)
Review Article
De-escalation of axillary treatment in early breast cancer—a narrative review of current trials
Translational Breast Cancer Research
2025;
6:
5
(24 January 2025)
Review Article
Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era
Translational Breast Cancer Research
2025;
6:
4
(24 January 2025)
Review Article
Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review
Translational Breast Cancer Research
2025;
6:
3
(24 January 2025)
Original Article
Underlying factors that affect ultrasound conspicuity of breast biopsy markers: an exploratory study
Translational Breast Cancer Research
2025;
6:
2
(24 January 2025)
Editorial
Unveiling breast cancer disparities: comparative insights from Asian and Western populations
Translational Breast Cancer Research
2025;
6:
1
(24 January 2025)
Case Report
A case report of interstitial lung disease caused by HER2-positive breast cancer patient receiving two antibody-drug conjugate drugs successively
Translational Breast Cancer Research
2024;
5:
36
(31 October 2024)
Editorial Commentary
Precision medicine for breast cancer: advances and challenges
Translational Breast Cancer Research
2024;
5:
35
(31 October 2024)
Editorial Commentary
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?
Translational Breast Cancer Research
2024;
5:
34
(31 October 2024)
Review Article
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Translational Breast Cancer Research
2024;
5:
33
(31 October 2024)
Review Article
Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer
Translational Breast Cancer Research
2024;
5:
32
(31 October 2024)